Skip to main navigation Skip to search Skip to main content

Current Management of Desmoid Tumors: A Review

  • Bernd Kasper*
  • , Elizabeth H. Baldini
  • , Sylvie Bonvalot
  • , Desmoid Tumor Working Group
  • , Dario Callegaro
  • , Kenneth Cardona
  • , Chiara Colombo
  • , Nadege Corradini
  • , Aimee M. Crago
  • , Angelo P. Dei Tos
  • , Palma Dileo
  • , Eldad Elnekave
  • , Joseph P. Erinjeri
  • , Fariba Navid
  • , Jeffrey M. Farma
  • , Andrea Ferrari
  • , Marco Fiore
  • , Rebecca A. Gladdy
  • , Mrinal Gounder
  • , Rick L. Haas
  • Olga Husson, Jean-Emmanuel Kurtz, Alex J. Lazar, Daniel Orbach, Nicolas Penel, Ravi Ratan, Chandrajit P. Raut, Christina L. Roland, Ann-Rose W. Schut, Monika Sparber-Sauer, Dirk C. Strauss, Winette T. A. van der Graaf, Marco Vitellaro, Aaron R. Weiss, Alessandro Gronchi
*Corresponding author for this work
  • Ruprecht Karl University of Heidelberg
  • Harvard University
  • Unicancer
  • Fondazione IRCCS Istituto Nazionale Tumori Milan
  • Emory University
  • Memorial Sloan-Kettering Cancer Center
  • Cornell University
  • University of Padua
  • Department Radiation Oncology
  • Hebrew University of Jerusalem
  • Children's Hospital Los Angeles
  • Fox Chase Cancer Center
  • University of Toronto
  • Netherlands Cancer Institute
  • Leiden University
  • Dept Med & Surg Oncol & Hematol
  • University of Texas System
  • Erasmus University Rotterdam
  • Klinikum Stuttgart
  • Royal Marsden NHS Foundation Trust
  • Maine Medical Center

Research output: Contribution to journal › Review article › Academic › peer-review

107 Citations (Scopus)
861 Downloads (Pure)

Abstract

Importance: Desmoid tumor (DT) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made. To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023, under the auspices of the European Reference Network on Rare Adult Solid Cancers and Sarcoma Patient Advocacy Global Network, the Desmoid Foundation Italy, and the Desmoid Tumor Research Foundation. The meeting brought together over 90 adult and pediatric sarcoma experts from different disciplines as well as patients and patient advocates from around the world. Observations: The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors. Literature searches of MEDLINE and Embase databases were performed for English-language randomized clinical trials (RCTs) of systemic therapies to obtain data to support the consensus recommendations. Of the 18 full-text articles retrieved, only 4 articles met the inclusion criteria. The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT. Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients. Conclusions and Relevance: The therapeutic armamentarium of DT therapy is continually expanding. It is imperative to carefully select the management strategy for each patient with DT to optimize tumor control and enhance quality of life.

Original languageEnglish
Pages (from-to)1121-1128
Number of pages8
JournalJAMA Oncology
Volume10
Issue number8
Early online date20 Jun 2024
DOIs
Publication statusPublished - 15 Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 American Medical Association. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Current Management of Desmoid Tumors: A Review'. Together they form a unique fingerprint.

Cite this